Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Corey Goodman - aVenture Research

Corey Goodman

AddedMar 31, 2024

UpdatedOct 12, 2026

Corey Goodman

Corey Goodman

Co-Founder, Exelixis

Corey Goodman's Career

ALX Oncology Holdings

Corey Goodman's Co-Investors

Franklin BergerCo-invested · MindRhythm Seed

Pierre LamondCo-invested · MindRhythm Seed

Kyle YorkCo-invested · MindRhythm Seed

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Corey Goodman's Investments

3 investments since 2017

2 operating · 1 inactive

Investments view

Group by

2021

1

MindRhythm
Seed · August 2021$5M
Seed · August 2021

2019

1

Queenly
Pre-Seed · October 2019$800k
Pre-Seed · October 2019

2017

1

Good2Go
Seed · September 2017$7M
Seed · September 2017

PublicSouth San Francisco, CA, US

Board Member· Board

Exelixis

Public$514MAlameda, CA, US

Co-Founder

Tallac Therapeutics

Series A$88.2MBurlingame, CA, US

Co-Founder

Renovis Surgical Technologies

$10.7MRedlands, CA, US

Founder

NeuroTherapeutics Pharma

Public$60.7MChicago, IL, US

Board Member· Board

Solstice Biologics

Series C$47.5MSan Francisco, CA, US

Board Member· Board

Second Genome

$62.5MSouth San Francisco, CA, US

Board Member· Board

Fog Pharmaceuticals

Series D$385.3MCambridge, MA, US

Board Member· Board

David LamondCo-invested · MindRhythm Seed

Robert HessCo-invested · Queenly Pre-Seed

Manik GuptaCo-invested · Queenly Pre-Seed

Thuan PhamCo-invested · Queenly Pre-Seed

Jared SchrieberCo-invested · Queenly Pre-Seed

People Similar to Corey Goodman

Stephen BlochBoard Member · Liquidia

Thilo SchroederBoard Member · Nextech Invest

Phil JohnsonBoard Member · Loxo Oncology

Steve GillisBoard Member · Takeda

Leadership at ALX Oncology Holdings

Jaume PonsFounder

Jack NielsenBoard Member

Jason LettmannBoard Member

Similar to ALX Oncology Holdings

Allterum TherapeuticsHouston, TX, USCancer Treatment, Immunotherapyest. 2018Allterum TherapeuticsHouston, TX, US · est. 2018

Biopharmaceutical firm, Allterum Therapeutics, innovates immunotherapies for various IL-7R expressing cancers.

CybrexaNew Haven, CT, USOncology, Therapeuticsest. 2017CybrexaNew Haven, CT, US · est. 2017

Cybrexa Therapeutics: A clinical-stage biotech firm, innovating in oncology with DNA repair inhibitors.

Series B · $44.4M38

Alaunos TherapeuticsHouston, TX, USCancer Treatmentest. 2005Alaunos TherapeuticsHouston, TX, US · est. 2005

Alaunos Therapeutics: A global clinical-stage company specializing in TCR-T cell therapy for solid tumors.

Public · $293.4M34

OncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30

Leadership at Exelixis

George PosteBoard Member

Stelios PapadopoulosBoard Member

Mike MorrisseyCEO

Jack L. WyszomierskiBoard Member

Ramesh BaligaVice President of Biotherapeutics

Similar to Exelixis

Clovis OncologyBoulder, CO, USCancer Treatmentsest. 2009Clovis OncologyBoulder, CO, US · est. 2009

Clovis Oncology, a global biotech firm, specializes in developing and commercializing cancer treatments.

Public · $145M413

Leadership at Tallac Therapeutics

Peter DudekBoard Member

Hong I. WanCo-Founder

Ayman KabakibiCo-Founder

Similar to Tallac Therapeutics

Tactiva TherapeuticsBuffalo, NY, USCancer Treatmentest. 2016Tactiva TherapeuticsBuffalo, NY, US · est. 2016

Tactiva Therapeutics: Specializing in potent dual T cell receptor cancer immunotherapy.

Series A · $35M30

Bolt BiotherapeuticsRedwood City, CA, USCancer Therapeuticsest. 2015Bolt BiotherapeuticsRedwood City, CA, US · est. 2015

Bolt Biotherapeutics: A biotech firm developing immune-stimulating cancer therapeutics, traded publicly in the US.

Public · $198.5M91

Torl BiotherapeuticsCulver City, CA, USCancer Therapeuticsest. 2018Torl BiotherapeuticsCulver City, CA, US · est. 2018

Culver City-based TORL-Bio, advancing novel antibody-based cancer therapeutics since 2018.

Series B · $158M18

Janux TherapeuticsSan Diego, CA, USDrug Development, Immunotherapyest. 2017Janux TherapeuticsSan Diego, CA, US · est. 2017

Janux Therapeutics: Innovating safe, effective immunotherapies using proprietary TRACTr technology.

Public · $252.4M70

Similar to Renovis Surgical Technologies

RevOrthoGreat Neck, NY, USMedical Devicesest. 2013RevOrthoGreat Neck, NY, US · est. 2013

RevOrtho, a NY-based medical device company, innovates in orthopedic technology for enhanced implants and individualized solutions.

Tenon MedicalLos Gatos, CA, USMedical Devices, Surgical Devicesest. 2012Tenon MedicalLos Gatos, CA, US · est. 2012

Tenon Medical develops surgical implant systems and fusion devices for sacroiliac joint disorders.

Public · $12.8M26

Optimotion ImplantsOrlando, FL, USKnee Implants, Surgical Instrumentsest. 2016Optimotion ImplantsOrlando, FL, US · est. 2016

Optimotion Implants designs and manufactures advanced knee replacement systems for active patients.

Tyber MedicalMorristown, NJ, USMedical Devicesest. 2012Tyber MedicalMorristown, NJ, US · est. 2012

Tyber Medical: Developing, manufacturing, and marketing orthopedic and spinal implants.

Seed · $225k163

Leadership at NeuroTherapeutics Pharma

Stephen CollinsBoard Member

Luke EvninBoard Member

Fran HellerBoard Member

Dr Thomas R Beck "Tom"Board Member

Christine E SiuBoard Member

Elaine V. JonesBoard Member

Similar to NeuroTherapeutics Pharma

NeuroPro TherapeuticsYachats, OR, USPharmaceuticalsest. 2014NeuroPro TherapeuticsYachats, OR, US · est. 2014

NeuroPro Therapeutics: Developing pharmaceutical solutions for epilepsy and neurological disorders.

Series A · $5.1M5

Leadership at Solstice Biologics

Lou TartagliaBoard Member

Robert AdelmanBoard Member

Curt BradshawFounder

Similar to Solstice Biologics

NucleonicsHorsham, PA, USBiomedical Products, Therapeuticsest. 2001NucleonicsHorsham, PA, US · est. 2001

Global provider of innovative biomedical products, specializing in RNA interference therapeutics.

Series B · $51.4M30

SirnaomicsGaithersburg, MD, USTherapeuticsest. 2007SirnaomicsGaithersburg, MD, US · est. 2007

US-based Sirnaomics, Inc. is a biopharmaceutical firm specializing in ocular neovascularization therapeutics.

Public · $268M30

Silence TherapeuticsLondon, Greater London, GBRNA Therapeuticsest. 1994Silence TherapeuticsLondon, Greater London, GB · est. 1994

UK biotech co. discovering molecules with RNA tech to target genes in diseases with unmet needs.

Public · $248.7M120

Solve TherapeuticsBelmont, CA, USDrug Developmentest. 2021Solve TherapeuticsBelmont, CA, US · est. 2021

Solve Therapeutics: A California-based biopharmaceutical firm innovating in antibody drug conjugates since 2021.

Series A · $126M19

Leadership at Second Genome

Brad MargusBoard Member

Jill CarrollBoard Member

Janet WarringtonCo-Founder

Todd DeSantisCo-Founder

Karim DabbaghBoard Member

Mike CarusiBoard Member

Similar to Second Genome

Microbiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30

Leadership at Fog Pharmaceuticals

Barbara WeberBoard Member

Rick KlausnerBoard Member

Gregory L. VerdineCo-Founder

Weiqing ZhouCo-Founder

Edward FitzgeraldBoard Member

Jeffrey LeerinkBoard Member

Similar to Fog Pharmaceuticals

Foghorn TherapeuticsCambridge, MA, USDrug Development, Pharmaceuticalsest. 2015Foghorn TherapeuticsCambridge, MA, US · est. 2015

Foghorn Therapeutics Inc., a US-based pharmaceutical company, innovates novel drugs for cancer and serious disorders.

Public · $111M161

Blueprint MedicinesCambridge, MA, USCancer Treatmentsest. 2008

Blueprint MedicinesCambridge, MA, US · est. 2008

Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.

Public · $2.4B641

AthenexBuffalo, NY, USCancer Treatmentsest. 2003AthenexBuffalo, NY, US · est. 2003

Athenex, Inc., a global biopharmaceutical firm in Shatin, China, specializes in discovering, developing, and commercializing innovative cancer treatments.

Public · $342.1M297

CytomX TherapeuticsSouth San Francisco, CA, USCancer Treatmentsest. 2010CytomX TherapeuticsSouth San Francisco, CA, US · est. 2010

CytomX Therapeutics: A US-based oncology-focused biopharmaceutical firm specializing in probody cancer treatments.

Public · $345.4M174

AptinyxEvanston, IL, USPharmaceuticalsest. 2015

AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12

NeuroviaSan Francisco, CA, USDrugs, Therapeuticsest. 2013NeuroviaSan Francisco, CA, US · est. 2013

NeuroVia, Inc.: A US-based biopharmaceutical company developing therapies for neurological diseases.

Public · $14M75

NeuropathixDoylestown, PA, USTherapeuticsest. 2010NeuropathixDoylestown, PA, US · est. 2010

Neuropathix: An American biopharmaceutical firm specializing in R&D of pain management therapies.

GenieBiomeNew York, USBiotech Productsest. 2020

GenieBiomeNew York, US · est. 2020

NY-based GenieBiome uses microbiome tech to develop treatments for various diseases, including precision medicine.

Series B · $11M30

Seres TherapeuticsCambridge, MA, USBiological Drugsest. 2010Seres TherapeuticsCambridge, MA, US · est. 2010

Seres Therapeutics, a US-based company, develops biological drugs to restore health by repairing dysbiotic microbiomes.

Public · $537.8M431

Petri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Frontier MedicinesSouth San Francisco, CA, USPrecision Medicine, Therapeuticsest. 2018

Frontier MedicinesSouth San Francisco, CA, US · est. 2018

Frontier Medicines, a US-based precision medicine firm, pioneers in developing treatments for previously undruggable diseases.

Series B · $244M128

Camino PharmaSan Diego, CA, USCancer Treatment, Drug Developmentest. 2014Camino PharmaSan Diego, CA, US · est. 2014

Camino Pharma: A tech startup pioneering first-in-class cancer and CNS disorder therapies.

Ambagon TherapeuticsSan Francisco, CA, USCancer Drugsest. 2020Ambagon TherapeuticsSan Francisco, CA, US · est. 2020

Ambagon: Innovating small molecule cancer drugs to stabilize oncogenic proteins interaction.

Series A · $198M57